BioLineRx names Philip A. Serlin as CEO
Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. Prior to joining BioLineRx, Mr. Serlin served as the Chief Financial and Operating Officer of Kayote Networks Ltd.
Before that, he served as the Chief Financial Officer of Tescom Software Systems Testing Ltd., an IT services company publicly traded in both Tel Aviv and London.
His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. Accounting Department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters.
Mr. Serlin currently serves as a Director at Vascular Biogenics Ltd..
Mr. Serlin is a CPA and holds a B.Sc. in Accounting from Yeshiva University and a Master’s degree in Economics and Public Policy from The George Washington University.
He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.
BioLineRx also appoints Mali Zeevi as Chief Financial Officer, effective October 10, 2016.
Ms. Zeevi joined BioLineRx in 2009 as its Director of Finance and Reporting and has served as its Senior Director of Finance and Reporting since 2011.
Before joining BioLineRx, Ms. Zeevi was employed by Tescom Software Systems Testing Ltd., her last position there being Vice President Finance. Ms. Zeevi also served as a CPA at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited.
She holds a B.A. in business and accountancy from the College of Management Academic Studies in Israel. ■
LATEST MOVES FROM Israel
- Teva appoints Kåre Schultz as CEO
- Immune Pharma appoints Tony Fiorino as COO
- Enzymotec appoints Dror Israel as CFO
- Intec Pharma appoints Jeffrey A. Meckler as CEO
- Foamix Pharmaceuticals names David Domzalski as CEO
More inside POST
Renren Q2 net revenues jumped 55.4% Earnings